Clinical Trials Logo

Non-small Cell Carcinoma clinical trials

View clinical trials related to Non-small Cell Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05451173 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Start date: October 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is delivered in combination with an immune checkpoint inhibitor. Treatments with SBRT or HypoFrx-RT for locally confined NSCLC show positive response which may be further augmented when they are combined with an immune checkpoint inhibitor. Currently, it is not understood what radiation dose is most suitable for such combined treatments and their clinical efficacy in the treatment of early stage (ES) NSCLC. Therefore, this study can help researchers gain insight into what a safe and effective SBRT or HypoFrx-RT dose will be when such radiotherapeutic approaches are combined with concurrent and adjuvant administration of an immune checkpoint inhibitor in the treatment of ES NSCLC.

NCT ID: NCT04695925 Not yet recruiting - EGFR Gene Mutation Clinical Trials

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations

TOP
Start date: January 4, 2021
Phase: Phase 3
Study type: Interventional

This is a phase III clinical trial aimed to compare the efficacy and safety of Osimertinib monotherapy and combination of Osimertinib, pemetrexed and carboplatin in untreated patients with advanced non-small cell lung cancer with concurrent EGFR and TP53 mutation.